SRR1432765
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.459
- COAGULATION+0.369
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.318
- PANCREAS_BETA_CELLS+0.270
- ESTROGEN_RESPONSE_LATE+0.252
- INFLAMMATORY_RESPONSE+0.240
- MYOGENESIS+0.239
- BILE_ACID_METABOLISM+0.226
- KRAS_SIGNALING_UP+0.193
- IL6_JAK_STAT3_SIGNALING+0.186
Top 10 suppressed
- MYC_TARGETS_V1-0.592
- DNA_REPAIR-0.552
- MYC_TARGETS_V2-0.526
- OXIDATIVE_PHOSPHORYLATION-0.497
- UNFOLDED_PROTEIN_RESPONSE-0.495
- PROTEIN_SECRETION-0.461
- MTORC1_SIGNALING-0.440
- CHOLESTEROL_HOMEOSTASIS-0.402
- PI3K_AKT_MTOR_SIGNALING-0.400
- TGF_BETA_SIGNALING-0.334
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1444559 | GTEX | — | 0.977 |
| 2 | SRR1455698 | GTEX | — | 0.976 |
| 3 | SRR1476614 | GTEX | — | 0.969 |
| 4 | SRR1392725 | GTEX | — | 0.969 |
| 5 | SRR1343197 | GTEX | — | 0.969 |
| 6 | SRR1418604 | GTEX | — | 0.966 |
| 7 | SRR819793 | GTEX | — | 0.965 |
| 8 | SRR1455305 | GTEX | — | 0.962 |
| 9 | SRR1475022 | GTEX | — | 0.958 |
| 10 | SRR820292 | GTEX | — | 0.954 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.459 | Remibrutinib | — uncovered |
| COAGULATION | 0.369 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.318 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.270 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.252 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.240 | Idelalisib | — uncovered |
| MYOGENESIS | 0.239 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.226 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.193 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.186 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.150 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.142 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.142 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.133 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.121 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.112 | Temsirolimus | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.094 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.091 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.076 | Idelalisib | — uncovered |
| COMPLEMENT | 0.061 | Inavolisib | — uncovered |